Difficult intrauterine contraception insertion in a nulligravid patient

Obstetrics and Gynecology

Volumn 117, Issue 2 PART 1, 2011, Pages 391-395

  Vickery, Zevidah ^a   Madden, Tessa ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COPPER INTRAUTERINE DEVICE; LEVONORGESTREL; MISOPROSTOL;

ADULT; ARTICLE; CANCER SCREENING; CASE REPORT; CHLAMYDIA TRACHOMATIS; DYSMENORRHEA; ECTOPIC PREGNANCY; ENDOMETRITIS; FEMALE; FEMALE INFERTILITY; GONORRHEA; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; INTRAUTERINE DEVICE EXPULSION; LEIOMYOMA; MENORRHAGIA; MENSTRUAL CYCLE; MENSTRUAL IRREGULARITY; NULLIPARA; PARENTAL CONSENT; PELVIC INFLAMMATORY DISEASE; PLACENTAL DELIVERY; PRIORITY JOURNAL; RISK FACTOR; TREATMENT CONTRAINDICATION; UTERINE CERVICITIS; UTERINE CERVIX; UTERINE CERVIX CANCER; UTERINE CERVIX DILATATION; UTERUS MALFORMATION;

ANESTHESIA, CONDUCTION; FEMALE; GRAVIDITY; HUMANS; INTRAUTERINE DEVICES, MEDICATED; MISOPROSTOL; OXYTOCICS; PREGNANCY; YOUNG ADULT;

EID: 79251535604     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e318203ef78     Document Type: Article

References (26)

1. World Health Organization. Medical eligibility criteria for contraceptive use. 3rd ed. Geneva: World Health Organization; 2004.
2. Centers for Disease Control and Prevention. U.S. Medical Eligibility Criteria for Contraceptive Use, 2010. MMWR Early Release 2010;59:52-63.
3. Grimes DA. Intrauterine device and upper-genital-tract infection. Lancet 2000;356:1013-9.
4. Farley TM, Rosenberg MJ, Rowe PJ, Chen JH, Meirik O. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet 1992;339:785-8.
5. Madden T, Allsworth JE, Hladky KJ, Secura GM, Peipert JF. Intrauterine contraception in Saint Louis: a survey of obstetrician and gynecologists' knowledge and attitudes. Contraception 2010;81:112-6.
6. Hubacher D, Lara-Ricalde R, Taylor DJ, Guerra-Infante F, Guzmán-Rodríguez R. Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women. N Engl J Med 2001;345:561-7.
7. Hubacher D, Reyes V, Lillo S, Zepeda PL, Croxatto H. Copper intrauterine device use by nulliparous women: review of side effects. Contraception 2007;75(6 suppl):S8-11.
8. Suhonen S, Haukkamaa M, Jakobsson T, Rauramo I. Clinical performance of a levonorgestrel-releasing intrauterine system and oral contraceptives in young nulliparous women: a comparative study. Contraception 2004;69:407-12.
9. Increasing use of contraceptive implants and intrauterine devices to reduce unintended pregnancy. ACOG Committee Opinion No. 450. American College of Obstetricians and Gynecologists. Obstet Gynecol 2009;114:1434-8.
10. White MK, Ory HW, Rooks JB, Rochat RW. Intrauterine device termination rates and the menstrual cycle day of insertion. Obstet Gynecol 1980;55:220-4.
11. Family Health International. How to be reasonably sure a client is not pregnant. 2008. Available at: http://www.fhi.org/en/RH/Pubs/servdelivery/ checklists/pregnancy/index.htm. Retrieved May 12, 2010.
12. Grimes DA, Lopez LM, Schulz KF, Van Vliet HA, Stan-wood NL. Immediate post-partum insertion of intrauterine devices. The Cochrane Database of Systematic Reviews 2010, Issue 5. Art. No.: CD003036. DOI: 10.1002/14651858. CD003036.pub2.
13. Kapp N, Curtis KM. Intrauterine device insertion during the postpartum period: a systematic review. Contraception 2009; 80:327-36.
14. US Preventive Services Task Force. Screening for chlamydial infection: recommendations and rationale. Am J Prev Med 2001;20(3 suppl):90-4.
15. U.S. Preventive Services Task Force. Screening for gonorrhea: recommendation statement. Ann Fam Med 2005;3:263-7.
16. Sawaya GF, Harper C, Balistreri E, Boggess J, Darney P. Cervical neoplasia risk in women provided hormonal contraception without a Pap smear. Contraception 2001;63:57-60.
17. Stewart FH, Harper CC, Ellertson CE, Grimes DA, Sawaya GF, Trussell J. Clinical breast and pelvic examination requirements for hormonal contraception: current practice vs evidence. JAMA 2001;285:2232-9.
18. Westoff C. IUDs and colonization or infection with Actinomy-ces. Contraception 2007;75(6 suppl):S48-50.
19. Sääv I, Aronsson A, Marions L, Stephansson O, Gemzell-Danielsson K. Cervical priming with sublingual misoprostol prior to insertion of an intrauterine device in nulliparous women: a randomized controlled trial. Hum Reprod 2007;22: 2647-52.
20. Heikinheimo O, Inki P, Kunz M, Parmhed S, et al. Double-blind, randomized, placebocontrolled study on the effect of misoprostol on ease of consecutive insertion of the levonorg-estrel-releasing intrauterine system. Contraception 2010; 81;481-6.
21. Allen RH, Bartz D, Grimes DA, Hubacher D, O'Brien P. Interventions for pain with intrauterine device insertion. The Cochrane Database of Systematic Reviews 2009, Issue 3 Art. No.: CD007373. DOI: 10.1002/14651858.CD007373.pub2.
22. Baldaszti E, Wimmer-Puchinger B, Lö schke K. Acceptability of the long-term contraceptive levonorgestrel-releasing intra-uterine system (Mirena): a 3-year follow-up study. Contraception 2003;67:87-91.
23. Hubacher D, Chen PL, Park S. Side effects from the copper IUD: do they decrease over time? Contraception 2009;79: 356-62.
24. Guttmacher Institute. State policies in brief: an overview of minors' consent law. Available at: http://www.guttmacher. org/statecenter/spibs/spib OMCL.pdf. Retrieved October 5, 2009.
25. Kim SK, Romero R, Kusanovic JP, Erez O, Vaisbuch E, Masaki-Tovi S, et al. The prognosis of pregnancy conceived despite the presence of an intrauterine device (IUD). J Perinat Med. 2010;38:45-53.
26. Intrauterine device. ACOG Practice Bulletin No. 59. American College of Obstetricians and Gynecologists. Obstet Gynecol 2005;105:223-32.